Scarica l'app Stockscreener
9.855
4.04%
-0.565
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Omeros Corporation Borsa (OMER) Ultime notizie
Novo Nordisk Moves Into Renal Disease Via Pact With Omeros - insights.citeline.com
The Terrific Ten Undercard: OMER, VERI, SNYR, MYSE, RDZN – Stocks Under $5 (Complete List Inside) - FinancialContent
Omeros Corporation (OMER) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Small Biotech Catapults 154% On A $2.1 Billion Novo Deal - Investor's Business Daily
Novo Nordisk Just Signed a Key Drug Deal With Omeros. Is There Any Room Left for OMER Stock to Run? - Barchart.com
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Benzinga
Novo Offers up to $2.1B for Omeros’ Complement Drug To Expand Rare Disease Work - BioSpace
OMER: Needham Reiterates Hold Rating | OMER Stock News - GuruFocus
Omeros Rockets Skyward on $2.1 Billion Novo Nordisk Deal, Reshaping Biotech Landscape - FinancialContent
Bank Of America, Morgan Stanley, ASML, Omeros, Progressive: Stocks Making The Biggest Moves Today - Stocktwits
Novo Nordisk and Omeros Corporation Enters into Definitive Asset Purchase and License Agreement - MarketScreener
Omeros (OMER) Stock Jumps 140% Following $2 Billion Novo Nordisk Deal - parameter.io
Omeros Corporation stock outlook for YEARTrade Risk Assessment & Fast Gain Stock Tips - newser.com
OMER: WBB Securities Reiterates Strong Buy Rating, Price Target Held at $45.00 | OMER Stock News - GuruFocus
Can OMER stock retain Novo Nordisk driven gains over the long-term? - CryptoRank
Omeros Stock Soars 149% After $2.1 Billion Deal With Novo Nordisk - Nasdaq
Novo Nordisk Licenses Omeros' Rare Disease Drug For $2.1B - Law360
Quantitative breakdown of Omeros Corporation recent moveMarket Weekly Review & Safe Capital Growth Tips - newser.com
Omeros Stock (OMER) Surges 140% on Novo Nordisk (NVO) Deal - TipRanks
Omeros Stock Explodes 146% on Surprise $2.1B Novo Nordisk Deal – What Comes Next? - ts2.tech
Novo Nordisk to Buy Blood Disease Drug From Omeros for Up to $2.1 Billion - The Wall Street Journal
Novo Nordisk Expands Rare Disease Portfolio through $2.1 Billion Licensing Deal with Omeros - NAVLIN DAILY
Omeros Stock Soars After $2.1 Billion Licensing Deal with Novo Nordisk - MSN
Omeros price target raised to $20 from $9 at H.C. Wainwright - TipRanks
Novo Nordisk Secures $2.1 Billion Licensing Agreement with Omeros to Advance Rare Disease Treatments - Emegypt
Novo wagers up to $2.1B on Omeros’ rare disease drug - Yahoo Finance
OMER: Analyst Jason Kolbert Maintains 'Buy' Rating and $36 Targe - GuruFocus
Omeros set for best day ever on signing up to $2.1 billion licensing deal with Novo - TradingView
Novo Nordisk signs up to $2.1 billion licensing deal with Omeros in rare disease push - Reuters
Omeros rockets on news of deal with Novo Nordisk - The Pharma Letter
Novo Nordisk’s Surprise $2.1B Rare-Disease Acquisition Deal: What You Need to Know - ts2.tech
Omeros (OMER) Stock Skyrockets Following $2.1B Deal with Novo No - GuruFocus
Will Omeros Corp Bounce Back? - StocksToTrade
Novo Buys Omeros Rare-Disease Drug for as Much as $2.1 Billion - Bloomberg.com
Omeros (OMER) Shares Surge 124% Following New License Agreement - GuruFocus
Novo Nordisk acquires zaltenibart drug candidate from Omeros - MarketScreener
Omeros Corp Stock Soars A Whopping 136% Pre-Market After Novo Nordisk Agrees To Buy Its Drug Candidate For Blood Disorder - NewsBreak: Local News & Alerts
Omeros triples after signing up to $2.1 billion licensing deal with Novo Nordisk - TradingView
Novo Nordisk to Pay Omeros Up to $2.1 Billion for Blood Disease Drug - MarketScreener
Omeros Signs Major Deal with Novo Nordisk - TipRanks
Novo Nordisk pens $2.1B deal for Omeros’ stalled PNH drug - Fierce Biotech
Omeros stock spikes on Novo licensing deal (OMER:NASDAQ) - Seeking Alpha
Novo Nordisk opens its wallet again – agreement with Omeros - Biostock
Omeros stock soars after $2.1 billion deal with Novo Nordisk - Investing.com
Novo Nordisk and Omeros announce asset purchase and license - GlobeNewswire
Novo Nordisk and Omeros announce asset purchase and license agreement for Omeros’ clinical-stage MASP-3 inhibitor zaltenibart (OMS906) - Yahoo Finance
Intraday pattern recognizer results for Omeros CorporationJuly 2025 Big Picture & Safe Entry Momentum Stock Tips - newser.com
Wealth Enhancement Advisory Services LLC Has $84,000 Stock Holdings in Omeros Corporation $OMER - Defense World
Can Omeros Corporation stock sustain institutional interestBull Run & Capital Efficient Trading Techniques - newser.com
Omeros (NASDAQ:OMER) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
What institutional flow reveals about Omeros CorporationTrade Exit Report & Advanced Swing Trade Entry Plans - newser.com
Lobbying Update: $30,000 of OMEROS CORPORATION lobbying was just disclosed - Quiver Quantitative
Omeros surges 22% on clarity for BLA resubmission for narsoplimab - MSN
How to build a dashboard for Omeros Corporation stockWeekly Earnings Recap & Expert Approved Trade Ideas - newser.com
Retail investors who hold 53% of Omeros Corporation (NASDAQ:OMER) gained 10%, institutions profited as well - simplywall.st
Mydriasis Market: Epidemiology, Therapies, and Key Players include Théa Laboratories, Omeros Corporation, Ocuphire Pharma. - Barchart.com
4.90%
0.07%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):